# A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

> **NCT04372186** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 377 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04372186
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-14
- **Primary completion:** 2020-08-18
- **Final completion:** 2020-09-22
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04372186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04372186, "A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04372186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*